Literature DB >> 14531801

Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease.

Alan D Salama1, Afzal N Chaudhry, Kathryn A Holthaus, Karen Mosley, Raghu Kalluri, Mohamed H Sayegh, Robert I Lechler, Charles D Pusey, Liz Lightstone.   

Abstract

BACKGROUND: Goodpasture's, or anti-glomerular basement membrane (GBM), disease is unusual among autoimmune diseases in that it rarely follows a relapsing-remitting course. Moreover, untreated, autoantibodies disappear spontaneously after 1 to 3 years and, following treatment, autoreactive T cells diminish in frequency. This suggests that operational tolerance toward the autoantigen is reestablished. However, the mechanisms underlying this have remained unclear. Recent data have suggested that a population of regulatory T lymphocytes can suppress both autoimmune and alloimmune responses in animal models and are present in normal individuals. However, to date, they have not been demonstrated to play a role in human renal autoimmune disease.
METHODS: We studied the role of regulatory CD25+ cells in suppressing T-cell responses to the Goodpasture autoantigen in nine patients with Goodpasture's disease.
RESULTS: At the time of acute presentation, there was no evidence of a regulatory cell population. However, from 3 months onward a population emerged, capable of suppressing the response to the Goodpasture autoantigen. Following depletion of CD25+ cells, the frequencies of autoreactive-, GBM-, or collagen alpha 3(IV)NC1-specific T cells were significantly increased (P = 0.031 by paired t test), with five of seven (71%) convalescent patients and no acute patients demonstrating regulation.
CONCLUSION: These data demonstrate that, in Goodpasture's disease, regulatory CD25+ T cells play a role in inhibiting the autoimmune response. Their emergence and persistence may underlie the "single hit" nature of this condition. Understanding the conditions required for the development and propagation of these cells would allow development of novel therapeutic strategies for inducing hyporesponsiveness in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531801     DOI: 10.1046/j.1523-1755.2003.00259.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  31 in total

Review 1.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

2.  CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis.

Authors:  Jan-Eric Turner; Hans-Joachim Paust; Oliver M Steinmetz; Anett Peters; Jan-Hendrik Riedel; Annette Erhardt; Claudia Wegscheid; Joachim Velden; Susanne Fehr; Hans-Willi Mittrücker; Gisa Tiegs; Rolf A K Stahl; Ulf Panzer
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

Review 3.  Basement membranes and autoimmune diseases.

Authors:  Mary H Foster
Journal:  Matrix Biol       Date:  2016-08-02       Impact factor: 11.583

Review 4.  Cutting edge issues in Goodpasture's disease.

Authors:  Andrew L Chan; Samuel Louie; Kevin O Leslie; Maya M Juarez; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

5.  Induced regulatory T cells are phenotypically unstable and do not protect mice from rapidly progressive glomerulonephritis.

Authors:  Joanna R Ghali; Maliha A Alikhan; Stephen R Holdsworth; A Richard Kitching
Journal:  Immunology       Date:  2016-10-10       Impact factor: 7.397

Review 6.  Advances in human antiglomerular basement membrane disease.

Authors:  Zhao Cui; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

7.  A role for alphabeta T cells in the resistant phase of the Brown Norway rat model of vasculitis.

Authors:  C S Vinen; D R Turner; D B G Oliveira
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

8.  Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells.

Authors:  N M Lerret; J L Houlihan; T Kheradmand; K L Pothoven; Z J Zhang; X Luo
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

9.  IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen.

Authors:  Joshua D Ooi; Richard K S Phoon; Stephen R Holdsworth; A Richard Kitching
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

Review 10.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.